Longer time to all-cause antipsychotic discontinuation is associated with better schizophrenia treatment outcomes

被引：0
|
作者：
Dunayevich, E
Zhao, FY
Ascher-Svanum, H
Mitchell, CP
Phillips, GA
Dellva, MA
Green, A
机构：
[1] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
[2] Dartmouth Hlth & Med Ctr, Dartmouth Med Sch, Dept Psychiat, Lebanon, NH USA
来源：
BIOLOGICAL PSYCHIATRY | 2005年 / 57卷 / 08期
关键词：
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
390
引用
收藏
页码：107S / 107S
页数：1
相关论文
共 50 条
  • [1] Longer time to all-cause antipsychotic discontinuation is associated with better schizophrenia treatment outcomes
    Dunayevich, E
    Zhao, F
    Ascher-Svanum, H
    Mitchell, C
    Phillips, G
    Dellva, MA
    Green, A
    EUROPEAN PSYCHIATRY, 2005, 20 : S95 - S96
  • [2] Increased time to all-cause antipsychotic trial discontinuation is associated with better schizophrenia treatment outcomes
    Zhao, F
    Ascher-Svanum, H
    Mitchell, CP
    Phillips, GA
    Dunayevich, E
    SCHIZOPHRENIA BULLETIN, 2005, 31 (02) : 508 - 508
  • [3] Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder
    Dunayevich, Eduardo
    Ascher-Svanum, Haya
    Zhao, Fangyi
    Jacobson, Jennie G.
    Phillips, Glenn A.
    Dellva, Mary Anne
    Green, Alan I.
    JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 (08) : 1163 - 1171
  • [4] Time to all-cause discontinuation following randomization to open-label olanzapine, risperidone, or conventional antipsychotic treatment for schizophrenia
    Ascher-Svanum, H
    Nyhuis, AW
    Tunis, SL
    Stevens, M
    BIOLOGICAL PSYCHIATRY, 2005, 57 (08) : 44S - 44S
  • [5] Time to All-Cause Treatment Discontinuation as the Primary Outcome in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Study
    Davis, Sonia M.
    Stroup, T. Scott
    Koch, Gary G.
    Davis, Clarence E.
    Rosenheck, Robert A.
    Lieberman, Jeffrey A.
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2011, 3 (02): : 253 - 265
  • [6] All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotic agents: An integrated analysis
    Stauffer, VL
    Beasley, CM
    Liu-Seifert, H
    Taylor, CC
    Dunayevich, E
    Davis, JM
    SCHIZOPHRENIA RESEARCH, 2006, 81 : 68 - 69
  • [7] Time to all-cause discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
    Swartz, MS
    Ascher-Svanum, H
    Faries, DE
    Tunis, SL
    Landbloom, R
    Swanson, J
    BIOLOGICAL PSYCHIATRY, 2005, 57 (08) : 44S - 44S
  • [8] Time to all-cause discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
    Swartz, M
    Zhu, B
    Ascher-Svanum, H
    Faries, D
    Tunis, S
    Landbloom, R
    Swanson, J
    SCHIZOPHRENIA BULLETIN, 2005, 31 (02) : 551 - 552
  • [9] TIME TO ALL-CAUSE TREATMENT DISCONTINUATION AFTER INITIATION OF ARIPIPRAZOLE ONCE-MONTHLY OR DAILY ORAL ATYPICAL ANTIPSYCHOTIC TREATMENT IN YOUNGER SCHIZOPHRENIA PATIENTS
    Such, P.
    De Jong-Laird, A. C.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2022, 56 (1_SUPPL): : 247 - 248
  • [10] Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis
    Soares-Weiser, Karla
    Bechard-Evans, Laura
    Lawson, Anthony Howard
    Davis, John
    Ascher-Svanum, Haya
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 (02) : 118 - 125
12345